Oleg Kurtenkov Selected Research

Thomsen-Friedenreich antigen

1/2020	Profiling of Naturally Occurring Antibodies to the Thomsen-Friedenreich Antigen in Health and Cancer: The Diversity and Clinical Potential.
1/2018	The Thomsen-Friedenreich Antigen-Specific Antibody Signatures in Patients with Breast Cancer.
1/2017	Hidden IgG Antibodies to the Tumor-Associated Thomsen-Friedenreich Antigen in Gastric Cancer Patients: Lectin Reactivity, Avidity, and Clinical Relevance.
1/2015	Increased Avidity of the Sambucus nigra Lectin-Reactive Antibodies to the Thomsen-Friedenreich Antigen as a Potential Biomarker for Gastric Cancer.
1/2014	Increased sialylation of anti-Thomsen-Friedenreich antigen (CD176) antibodies in patients with gastric cancer: a diagnostic and prognostic potential.
1/2013	The relation of the level of serum anti-TF, -Tn and -alpha-Gal IgG to survival in gastrointestinal cancer patients.
1/2009	The Thomsen-Friedenreich antigen and alphaGal-specific human IgG glycoforms: concanavalin A reactivity and relation to survival of cancer patients.
2/2003	Better survival of Helicobacter pylori infected patients with early gastric cancer is related to a higher level of Thomsen-Friedenreich antigen-specific antibodies.
8/2002	Expression of tumor-associated Thomsen-Friedenreich antigen (T Ag) in Helicobacter pylori and modulation of T Ag specific immune response in infected individuals.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Oleg Kurtenkov Research Topics

Disease

12	Neoplasms (Cancer) 01/2020 - 08/2002
9	Stomach Neoplasms (Stomach Cancer) 01/2017 - 08/2002
3	Breast Neoplasms (Breast Cancer) 01/2018 - 12/2009
2	Infections 01/2020 - 01/2012
2	Fibrosis (Cirrhosis) 01/2020 - 01/2018
1	Inflammation (Inflammations) 01/2018
1	Hepatitis C 01/2018
1	Chronic Hepatitis C 01/2018
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2013
1	Adenocarcinoma 12/2009

Drug/Important Bio-Agent (IBA)

13	Immunoglobulin G (IgG)IBA 01/2020 - 08/2002
12	AntibodiesIBA 01/2020 - 02/2003
9	Thomsen-Friedenreich antigenIBA 01/2020 - 08/2002
6	Biomarkers (Surrogate Marker)IBA 01/2020 - 06/2013
4	Immunoglobulin M (IgM)IBA 01/2018 - 02/2003
4	LectinsIBA 01/2017 - 01/2009
3	Polysaccharides (Glycans)IBA 01/2018 - 01/2012
2	GlycoconjugatesIBA 01/2020 - 01/2013
2	Glycoproteins (Glycoprotein)IBA 01/2020 - 12/2009
2	Antiviral Agents (Antivirals)IBA 01/2020 - 01/2018
2	AntigensIBA 01/2018 - 06/2008
2	polyacrylamideIBA 01/2018 - 01/2013
2	Immunoglobulin A (IgA)IBA 01/2018 - 01/2014
2	Immunoglobulins (Immunoglobulin)IBA 01/2018 - 12/2009
2	Mucin-1 (CA 15-3 Antigen)IBA 12/2009 - 06/2008
2	Genetic Markers (Genetic Marker)IBA 12/2009 - 06/2008
2	Immunoglobulin Km AllotypesIBA 12/2009 - 06/2008
2	Tumor Viral Antigens (Large T Antigen)IBA 02/2003 - 08/2002
2	Thomsen-Friedenreich antibodiesIBA 02/2003 - 08/2002
1	Ribavirin (Virazole)FDA LinkGeneric 01/2020
1	Broadly Neutralizing AntibodiesIBA 01/2020
1	N-Acetylneuraminic Acid (Sialic Acid)IBA 01/2018
1	thiocyanic acid (ammonium thiocyanate)IBA 01/2018
1	AgglutininsIBA 01/2018
1	FucoseIBA 06/2013
1	CarbohydratesIBA 01/2013
1	human ERBB2 proteinIBA 11/2010
1	Immunoglobulin Gm AllotypesIBA 11/2010
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2009
1	Concanavalin AIBA 01/2009
1	Immunoglobulin Allotypes (Immunoglobulin Allotype)IBA 06/2008
1	EpitopesIBA 08/2002

Therapy/Procedure

1	Therapeutics 01/2020
1	Immunotherapy 11/2010